Top life sciences deals of 2025 point to selective growth
Version 1
PharmaShots has published its “Top 20 Life Sciences Deals of 2025” list in partnership with DealForma, underscoring how strongly large-scale dealmaking returned to biopharma in 2025. The ranking spans M&A, licensing, and strategic transactions, with major deals including Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, Roche’s March 12, 2025 obesity collaboration with Zealand Pharma valued at up to $5.3 billion, and Bain Capital’s February 7, 2025 agreement to acquire Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group in a carve-out valued at about ¥510 billion, or roughly $3.3 billion. The broader backdrop points the same way: PharmaShots’ separate “Top 20 Healthcare IPOs of 2025” report described sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare, with high-value raises led by Medline Industries at $7.2 billion and notable support for scaled, revenue-generating, and technology-integrated platforms. Broader market data from DealForma and Deloitte suggest 2025 was a rebound year for life sciences transactions after a slower start, with buyers becoming more selective but still willing to pay for late-stage, commercial, or strategically differentiated assets. (pharmashots.com)
Why it matters: For veterinary professionals, this isn’t a companion animal deal story on its face, but it is a useful signal about where capital and strategic attention are moving across health care. When large human-health companies and investors prioritize obesity, CNS, specialty pharma, rare disease, AI-enabled platforms, and scaled commercial assets, that can shape competition for talent, manufacturing capacity, clinical development partners, and investor appetite across adjacent animal health and veterinary innovation markets. It also reinforces that buyers and public investors are favoring assets with clearer regulatory paths, stronger evidence packages, and commercial visibility, a pattern veterinary companies and practice-facing suppliers will be watching closely. The fundraising environment matters too: Blackstone’s closing of its $6.3 billion BXLS VI fund, now the largest life sciences vehicle of its kind, is another sign that substantial capital remains available for drug and medtech opportunities even in a more selective market. (dealforma.com)
What to watch: Watch for whether 2026 dealmaking spills further into animal health, diagnostics, and veterinary-adjacent platforms as investors look for more targeted, resilient growth opportunities. Also worth watching is whether private equity continues pursuing take-private and carve-out opportunities, as seen in CVC Capital Partners’ proposed roughly €10.9 billion acquisition of Recordati, and whether IPO investors keep rewarding AI-enabled, precision medicine, and care-delivery platforms. (deloitte.com)